Strecker The study was done before any recommendations were adopted specific to GLP-1s and when to stop the medication prior to surgery, Strecker said in her presentation at the American Academy of Orthopaedic Surgeons Annual Meeting
:max_bytes(150000):strip_icc()/Health-GettyImages-2219827987-cf32483d6c854df0ba239114420da85b.jpg)
Plaintiffs in Ozempic litigation report injuries that have substantially impacted their health and quality of life: Gastroparesis (stomach paralysis) causing severe vomiting, inability to digest food properly, and malnutrition requiring feeding tubes Non-arteritic anterior ischemic optic neuropathy (NAION) resulting in sudden, permanent vision loss affecting one or both eyes Ileus and intestinal obstruction requiring emergency hospitalization and surgical procedures Severe gastrointestinal complications including bowel perforation and chronic digestive dysfunction Gallbladder disease necessitating surgical removal Aspiration pneumonia from persistent vomiting and impaired gastric emptying Gastroparesis affects approximately 4% of the population, but studies show that patients with definite gastroparesis have a 5-year survival rate of only 67% considerably lower than the 81% expected survival rate in the general population

Constant J, Blann AD, Resplandy F, Parrot F, Seigneur M, and Renard M (1999)
Phase 2 trials testing 9 mg, 10 mg, and 16 mg doses have shown promising results with weight loss potentially approaching 20% or higher at maximum doses